标准化模型业务

Search documents
南模生物境外业务毛利率显著高于境内业务遭监管拷问
Xin Lang Zheng Quan· 2025-06-25 10:36
Core Insights - The company reported a total revenue of 381 million yuan for 2024, reflecting a year-on-year growth of 4.01%, with significant disparities in performance across different business segments [1] Group 1: Business Performance - The standardized model business generated revenue of 165 million yuan, up 16.58% year-on-year, driven by increased demand from research clients and improved cost control, with project numbers surging by 45% [2] - The model breeding business saw a revenue decline of 8.60% to 90.06 million yuan, primarily due to a significant drop in project prices, which fell from 20,600 yuan per project in 2023 to 14,400 yuan in 2024, overshadowing the growth in project numbers [2] - The overseas business revenue reached 53.06 million yuan, marking a 31.88% increase, with a gross margin of 70.9%, significantly outperforming the domestic business gross margin of 41.66% [2] Group 2: Customer Structure - Industrial clients contributed higher gross margins in standardized models and efficacy evaluation services, with average prices of 115,200 yuan per project compared to 22,900 yuan for research clients, and gross margins for industrial clients being 10-30 percentage points higher [3] Group 3: Inventory and Capacity Management - The company reduced its inventory balance to 12.67 million yuan, a decrease of 19.95% year-on-year, with an inventory turnover rate of 15 times, significantly higher than industry peers [4] - The company operates nine production bases with a total capacity of 140,000 cages, with a current capacity utilization rate of 80%, and plans to reduce reliance on leasing through a planned expansion project [4]
南模生物: 关于2024年年度报告的信息披露监管问询函的回复公告
Zheng Quan Zhi Xing· 2025-06-24 17:02
Core Viewpoint - The company has responded to the regulatory inquiry regarding its 2024 annual report, addressing various aspects of its business performance and financial metrics, particularly focusing on revenue changes across different segments and the impact of market conditions on its operations [1][2]. Business Performance - In 2024, the company reported total revenue of 381.24 million yuan, with standardized model revenue at 164.77 million yuan, showing a year-on-year increase of 16.58%. However, model breeding revenue decreased by 8.60% to 90.06 million yuan, while drug efficacy evaluation and phenotypic analysis revenue increased by 7.14% to 53.20 million yuan [2][4]. - Domestic and international revenue were 325.43 million yuan and 53.06 million yuan respectively, with gross margins of 41.66% and 70.9%, indicating a 31.88% year-on-year growth in international revenue [2][4]. Revenue Analysis - The company conducted a volume and price analysis of revenue changes across different business segments, noting that the increase in standardized model revenue was due to a rise in project quantity, while the decline in customized model revenue was attributed to a decrease in project quantity [3][5]. - The company observed a general decline in project prices across all business types due to intensified market competition and increased customer price sensitivity [4][5]. Customer Segmentation - The customer base primarily consists of research and industrial clients, with research clients having a higher number but lower average transaction values compared to industrial clients [6][8]. - The revenue contribution from research clients and industrial clients remained stable year-on-year, with customized model business mainly serving research clients [6][8]. Gross Margin Comparison - The gross margin for standardized models increased by 7.26 percentage points, attributed to stable demand from research clients and improved cost control measures [7][9]. - The gross margin for breeding services decreased by 13.97 percentage points due to increased market competition and underutilization of breeding facilities, leading to higher unit costs [7][9]. International Business Growth - The company expanded its international market presence, resulting in significant revenue growth from overseas operations, with higher average sales prices compared to domestic sales [10][12]. - The gross margin for international sales was significantly higher than domestic sales, reflecting industry norms [10][12]. Inventory Management - As of the end of 2024, the company's inventory balance was 12.67 million yuan, a decrease of 19.95% year-on-year, with inventory turnover rates significantly higher than industry peers [19][21]. - The reduction in inventory was attributed to improved cost control, production efficiency, and the completion of long-term projects, particularly in drug efficacy evaluation and phenotypic analysis [19][21].